BGB-11417-105 (NCT04973605) is a Phase 1b/2 dose-escalation and cohort-expansion trial of sonrotoclax as monotherapy, in combination with dexamethasone and carfilzomib/dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma harboring t(11;14).